Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU

Key Takeaways NVS received CHMP support for remibrutinib to treat CSU patients unresponsive to H1 antihistamines.Phase III REMIX studies showed improved itch, hives and quality of life through week 52.Rhapsido is FDA-approved and is also being studied for other immune-mediated diseases.Novartis (NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorization for remibrutinib as an oral tre ...